Cargando…

Increasing cure rates of solid tumors by immune checkpoint inhibitors

Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer immunity. Initially, ICIs were approved only for advanced and metastatic cancers in the salvage setting after or concurrent w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Weijie, Xue, Ruobing, Zhu, Zheng, Farrukh, Hizra, Song, Wenru, Li, Tianhong, Zheng, Lei, Pan, Chong-xian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843946/ https://www.ncbi.nlm.nih.gov/pubmed/36647169 http://dx.doi.org/10.1186/s40164-023-00372-8

Ejemplares similares

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors
por: Young, Richard Benjamin, et al.
Publicado: (2022)

Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
por: Crittenden, Marka R., et al.
Publicado: (2018)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
por: Chen, Yu, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Neurotoxicity
por: Zhao, Zhiyi, et al.
Publicado: (2021)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?
por: Sharma, Rajeev
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
por: Koustas, Evangelos, et al.
Publicado: (2020)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
por: Yang, Kaili, et al.
Publicado: (2020)

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
por: Yu, Yingyan
Publicado: (2021)

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
por: Kawashima, Shun, et al.
Publicado: (2022)

ICU admission for solid cancer patients treated with immune checkpoint inhibitors
por: Toffart, Anne-Claire, et al.
Publicado: (2023)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Prevalence of Depression and Anxiety amongst Cancer Patients in a Hospital Setting: A Cross-Sectional Study
por: Khalil, Anish, et al.
Publicado: (2016)

Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry
por: Ma, Weijie, et al.
Publicado: (2023)

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
por: Wright, Jordan J., et al.
Publicado: (2018)

Killer to cure: Expression and production costs calculation of tobacco plant‐made cancer‐immune checkpoint inhibitors
por: Ridgley, Laura A., et al.
Publicado: (2023)

Immune Checkpoints in Solid Organ Transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2023)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review
por: Liu, Xiaolin, et al.
Publicado: (2020)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors
por: Pan, Shen, et al.
Publicado: (2019)

Case of advanced pulmonary squamous cell carcinoma cured by resection through preoperative induction of immune checkpoint inhibitor
por: Kawai, Hideki, et al.
Publicado: (2018)

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
por: Chen, Yu, et al.
Publicado: (2020)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
por: Sindhu, Kunal K., et al.
Publicado: (2022)

Increased response to immune checkpoint inhibitors with dietary methionine restriction
por: Morehead, Lauren C., et al.
Publicado: (2023)

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
por: Kleponis, Jennifer, et al.
Publicado: (2015)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
por: Chu, Pei-Yi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a0e4o7f7rc0rgd8fpi9rbg9h7q